The recombinant subunit vaccine in COVID-19 is the recombinant COVID-19 vaccine (CHO cell) produced by Anhui Zhifeilong Koma Biopharmaceutical Co., Ltd. (Zhifeilong Koma). The vaccine is a recombinant subunit vaccine without viral nucleic acid components.
Taking the receptor binding domain (RBD) of COVID-19 S protein as the target, recombinant expression of RBD protein can induce human body to produce neutralizing antibodies, thus blocking the binding of COVID-19 to the host cell surface receptor ACE2, and achieving the purpose of preventing infection.
Introduction of recombinant COVID-19 vaccine;
Recombinant COVID-19 vaccine (CHO cells) needs to be inoculated with 3 doses; According to the instructions, it takes 60 days before and after inoculation in 0, 1 and February. It is suggested that the interval between two adjacent doses should be ≥4 weeks, the second dose should be completed within 8 weeks after 1 dose, and the third dose should be completed within 6 months after 1 dose.
Because the three doses of COVID-19 vaccine belong to recombination, different vaccine varieties play differently. There is one dose of COVID-19 vaccine, and now it is generally two doses on the market. When recombining this clinical trial, the effect of three needles is better than that of two needles, and the titer of neutralizing antibody produced is higher.
Comments?